Cargando…
Automated rare single cell picking with the ALS cellcelector™
Molecular analysis of rare single cells like circulating tumor cells (CTCs) from whole blood patient samples bears multiple challenges. One of those challenges is the efficient and ideally loss‐free isolation of CTCs over contaminating white and red blood cells. While there is a multitude of commerc...
Autores principales: | Nelep, Constantin, Eberhardt, Jens |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6586056/ https://www.ncbi.nlm.nih.gov/pubmed/30184320 http://dx.doi.org/10.1002/cyto.a.23568 |
Ejemplares similares
-
The RareCyte® platform for next‐generation analysis of circulating tumor cells
por: Kaldjian, Eric P., et al.
Publicado: (2018) -
Blood‐based biopsies—clinical utility beyond circulating tumor cells
por: Tang, Cha‐Mei, et al.
Publicado: (2018) -
The Parsortix™ Cell Separation System—A versatile liquid biopsy platform
por: Miller, M. Craig, et al.
Publicado: (2018) -
How to Agree on a CTC: Evaluating the Consensus in Circulating Tumor Cell Scoring
por: Zeune, Leonie L., et al.
Publicado: (2018) -
Centrifugation affects the purity of liquid biopsy‐based tumor biomarkers
por: Rikkert, Linda G., et al.
Publicado: (2018)